ViaCyte

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.

Timeline

June 19, 2021

ViaCyte raises $45M in Series D funding.

The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.

June 18, 2021

ViaCyte raises a $45,000,000 series D round.

May 26, 2020

ViaCyte raises a $27,000,000 series D round.

March 2020

ViaCyte raises a $32,600,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and TPG Capital Asia.

September 2018

ViaCyte raises a $10,000,000 convertible note from W. L. Gore and Associates.

December 2017

ViaCyte raises a $1,400,000 grant from California Institute for Regenerative Medicine.

July 2016

ViaCyte raises a $3,900,000 grant.

September 2014

ViaCyte raises a $16,600,000 grant from California Institute for Regenerative Medicine.

August 2014

ViaCyte raises a $5,400,000 series C round.

August 2014

ViaCyte raises a $20,000,000 venture round from Johnson & Johnson Innovation.

Funding Rounds

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes

Beyondtype1

https://beyondtype1.org/10-million-grant-to-viacyte-from-gore-supports-cell-based-treatment-for-diabetes/

Web

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

ViaCyte, Inc.

https://www.prnewswire.com/news-releases/center-for-beta-cell-therapy-in-diabetes-and-viacyte-announce-start-of-european-clinical-trial-of-human-stem-cell-derived-implants-in-type-1-diabetes-patients-300781276.html

Web

CRISPR Therapeutics and Viacyte launch diabetes partnership

BIOCOM AG

https://european-biotechnology.com/up-to-date/latest-news/news/crispr-therapeutics-and-viacyte-launch-diabetes-partnership.html

Web

ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial

Benedict Jephcote

https://www.diabetes.co.uk/news/2018/jun/viacyte-encapsulated-islet-cells-show-survival-success-in-type-1-diabetes-trial-95478678.html

Web

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

ViaCyte, Inc.

https://www.prnewswire.com/news-releases/viacyte-secures-80-million-financing-to-advance-functional-cures-for-insulin-requiring-diabetes-300757190.html

Web

News

Title

Author

Date

Publisher

Description

Stem cell biotech ViaCyte staffs up CSO role to drive diabetes treatments

Emmy Lucas

September 13, 2021

FierceBiotech

Months after raising $45 million and losing a chief scientific officer, stem cell-focused biotech ViaCyte has restaffed the position with a cell therapy academic from the University of British Columbia. Timothy Kieffer will join the clinical-stage regenerative medicine biotech as CSO.

ViaCyte Reports Compelling Preliminary Clinical Data from Islet Cell Replacement Therapy for Patients with Type 1 Diabetes

ViaCyte, Inc.

June 25, 2021

www.prnewswire.com:443

/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients...

ViaCyte Raises $45M in Funding | FinSMEs

FinSMEs

June 19, 2021

FinSMEs

ViaCyte extends series D by $45M one day after losing its chief scientific officer

Kyle LaHucik

June 9, 2021

FierceBiotech

ViaCyte snagged $45 million in a new tranche of financing to expand on a 2018 series D worth $80 million. The money will fund the biotech's work on two midstage candidates for type 1 diabetes, and it comes just a day after the biotech said its chief scientific officer is leaving.

ViaCyte Appoints Dr. Evert Kroon as Interim Chief Scientific Officer

BioSpace

June 8, 2021

BioSpace

ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.